Company Analysis
Sign in

Protagonist Therapeutics, Inc. (PTGX)

Nasdaq: PTGX · Pharmaceutical Preparations · Newark, CA · filing with the SEC since 2006
Full chart Alerts Compare
Grade5.7
◀ Past 4.3● Present 7.6▶ Future 4.9
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

33 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Protagonist Therapeutics, Inc.’s names, not what it holds today.

Patents granted
33
33 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 3 in 2024 and 4 in 2023
Applications published
81
7 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'14'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals10
Biotechnology4
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Protagonist Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
68 published
PROTAGONIST THERAPEUTICS, INC. its own name
US, as the owner printed on each patent
33 granted
13 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 25, 202512,478,617Lipidated peptide inhibitors of interleukin-23 receptorPharmaceuticalsPROTAGONIST THERAPEUTICS, INC.
Apr 8, 202512,269,856Hepcidin analogues and uses thereofPharmaceuticalsPROTAGONIST THERAPEUTICS, INC.
Feb 25, 202512,234,300Conjugated hepcidin mimeticsPharmaceuticalsPROTAGONIST THERAPEUTICS, INC.
Jun 25, 202412,018,057Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesBiotechnologyPROTAGONIST THERAPEUTICS, INC.
Mar 26, 202411,939,361Compositions of peptide inhibitors of Interleukin-23 receptorPharmaceuticalsPROTAGONIST THERAPEUTICS, INC.
Jan 30, 202411,884,748Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPharmaceuticalsPROTAGONIST THERAPEUTICS, INC.
Dec 19, 202311,845,808Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesBiotechnologyPROTAGONIST THERAPEUTICS, INC.
Dec 12, 202311,840,581α4β7 thioether peptide dimer antagonistsPharmaceuticalsPROTAGONIST THERAPEUTICS, INC.
Nov 7, 202311,807,674Hepcidin analogues and uses thereofPharmaceuticalsPROTAGONIST THERAPEUTICS, INC.
Sep 12, 202311,753,443Conjugated hepcidin mimeticsPharmaceuticalsPROTAGONIST THERAPEUTICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 27, 20252025/0361280CONJUGATED HEPCIDIN MIMETICSPharmaceuticalsProtagonist Therapeutics, Inc.
Nov 27, 20252025/0360187HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASEBiotechnologyPROTAGONIST THERAPEUTICS, INC.
Nov 6, 20252025/0340608HEPCIDIN ANALOGUES AND USES THEREOFPharmaceuticalsPROTAGONIST THERAPEUTICS, INC.
Oct 23, 20252025/0327065DISULFIDE-RICH PEPTIDE LIBRARIES AND METHODS OF USE THEREOFComputer technologyProtagonist Therapeutics, Inc.
Oct 2, 20252025/0304624CONJUGATED HEPCIDIN MIMETICSPharmaceuticalsProtagonist Therapeutics, Inc.
Sep 4, 20252025/0277012CONJUGATED HEPCIDIN MIMETICSPharmaceuticalsProtagonist Therapeutics, Inc.
May 29, 20252025/0170216CONJUGATED HEPCIDIN MIMETICSBiotechnologyProtagonist Therapeutics, Inc.
Dec 12, 20242024/0409598PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTORPharmaceuticalsProtagonist Therapeutics, Inc.
Nov 21, 20242024/0383954PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASESBiotechnologyProtagonist Therapeutics, Inc.
Oct 24, 20242024/0352073BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTORBiotechnologyProtagonist Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 16 · Biotechnology 8 · Computer technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton PTGX · research, not advice